Literature DB >> 21360265

Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development.

R Mark Payne1, P Melanie Pride, Clifford M Babbey.   

Abstract

Friedreich's ataxia is a multisystem disorder of mitochondrial function affecting primarily the heart and brain. Patients experience a severe cardiomyopathy that can progress to heart failure and death. Although the gene defect is known, the precise function of the deficient mitochondrial protein, frataxin, is not known and limits therapeutic development. Animal models have been valuable for understanding the basic events of this disease. A significant need exists to focus greater attention on the heart disease in Friedreich's ataxia, to understand its long-term outcome, and to develop new therapeutic strategies using existing medications and approaches. This review discusses some key features of the cardiomyopathy in Friedreich's ataxia and potential therapeutic developments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360265      PMCID: PMC3097037          DOI: 10.1007/s00246-011-9943-6

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  91 in total

1.  Targeting proteins to mitochondria using TAT.

Authors:  Victoria Del Gaizo; James A MacKenzie; R Mark Payne
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

2.  Studies on the internalization mechanism of cationic cell-penetrating peptides.

Authors:  Guillaume Drin; Sylvine Cottin; Emmanuelle Blanc; Anthony R Rees; Jamal Temsamani
Journal:  J Biol Chem       Date:  2003-06-03       Impact factor: 5.157

Review 3.  TAT-based drug delivery system--new directions in protein delivery for new hopes?

Authors:  Matan Rapoport; Haya Lorberboum-Galski
Journal:  Expert Opin Drug Deliv       Date:  2009-05       Impact factor: 6.648

4.  Biventricular function in Friedreich's ataxia: a radionuclide angiographic study.

Authors:  B Palagi; R Picozzi; F Casazza; M Possa; G Magri; O Zoccarato; E Graziano; F Ferrari; M Morpurgo
Journal:  Br Heart J       Date:  1988-06

5.  Friedreich's ataxia. Revision of the phenotype according to molecular genetics.

Authors:  L Schöls; G Amoiridis; H Przuntek; G Frank; J T Epplen; C Epplen
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

Review 6.  Friedreich ataxia.

Authors:  Massimo Pandolfo
Journal:  Arch Neurol       Date:  2008-10

7.  In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis.

Authors:  Guodong Cao; Wei Pei; Hailiang Ge; Qinhua Liang; Yumin Luo; Frank R Sharp; Aigang Lu; Ruiqiong Ran; Steven H Graham; Jun Chen
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

8.  Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants.

Authors:  Matthias L Jauslin; Thomas Meier; Robin A J Smith; Michael P Murphy
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

9.  In vivo maturation of human frataxin.

Authors:  Ivano Condò; Natascia Ventura; Florence Malisan; Alessandra Rufini; Barbara Tomassini; Roberto Testi
Journal:  Hum Mol Genet       Date:  2007-04-27       Impact factor: 6.150

10.  HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.

Authors:  Myriam Rai; Elisabetta Soragni; Kai Jenssen; Ryan Burnett; David Herman; Giovanni Coppola; Daniel H Geschwind; Joel M Gottesfeld; Massimo Pandolfo
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more
  10 in total

1.  Cardiomyopathy of Friedreich's ataxia (FRDA).

Authors:  R M Payne; R E Peverill
Journal:  Ir J Med Sci       Date:  2012-02-29       Impact factor: 1.568

2.  High-throughput immunoassay for the biochemical diagnosis of Friedreich ataxia in dried blood spots and whole blood.

Authors:  Devin Oglesbee; Charles Kroll; Oleksandr Gakh; Eric C Deutsch; David R Lynch; Ralitza Gavrilova; Silvia Tortorelli; Kimiyo Raymond; Dimitar Gavrilov; Piero Rinaldo; Dietrich Matern; Grazia Isaya
Journal:  Clin Chem       Date:  2013-07-09       Impact factor: 8.327

Review 3.  [Heart involvement in Friedreich's ataxia].

Authors:  F Weidemann; F Scholz; C Florescu; D Liu; K Hu; S Herrmann; G Ertl; S Störk
Journal:  Herz       Date:  2014-05-23       Impact factor: 1.443

Review 4.  Clinical features of Friedreich ataxia.

Authors:  Martin B Delatycki; Louise A Corben
Journal:  J Child Neurol       Date:  2012-06-29       Impact factor: 1.987

Review 5.  Friedreich ataxia: neuropathology revised.

Authors:  Arnulf H Koeppen; Joseph E Mazurkiewicz
Journal:  J Neuropathol Exp Neurol       Date:  2013-02       Impact factor: 3.685

6.  Relation of cytosolic iron excess to cardiomyopathy of Friedreich's ataxia.

Authors:  R Liane Ramirez; Jiang Qian; Paolo Santambrogio; Sonia Levi; Arnulf H Koeppen
Journal:  Am J Cardiol       Date:  2012-09-21       Impact factor: 2.778

Review 7.  Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia.

Authors:  Rachael A Vaubel; Grazia Isaya
Journal:  Mol Cell Neurosci       Date:  2012-08-11       Impact factor: 4.314

Review 8.  Neuro-Cardio Mechanisms in Huntington's Disease and Other Neurodegenerative Disorders.

Authors:  Bethan J Critchley; Mark Isalan; Michal Mielcarek
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

9.  Mitofusin-Dependent ER Stress Triggers Glial Dysfunction and Nervous System Degeneration in a Drosophila Model of Friedreich's Ataxia.

Authors:  Oliver Edenharter; Stephan Schneuwly; Juan A Navarro
Journal:  Front Mol Neurosci       Date:  2018-03-06       Impact factor: 5.639

10.  Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia.

Authors:  Wing-Hang Tong; Hayden Ollivierre; Audrey Noguchi; Manik C Ghosh; Danielle A Springer; Tracey A Rouault
Journal:  Heliyon       Date:  2022-08-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.